Dare Biosciences Inc. (NASDAQ: DARE) stock hiked by 10.52% at last close while the DARE stock price surged by 37.61% in the after-hours trading session. Dare Bioscience is a clinical-stage pharmaceutical firm dedicated to developing new women’s health products.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DARE stock’ Current Development
XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2 percent) (previously known as DARE-BV1) has been approved by the US Food and Drug Administration (FDA) for the cure of bacterial vaginosis in females aged 12 and above.
Sabrina Martucci Johnson, President and CEO of Daré Bioscience commented that,
The FDA’s clearance of XACIATO is a significant step forward not only for Daré as a company, but also for the 21 million women who suffer from bacterial vaginosis. As a company, they want to speed up the creation of unique solutions that can enhance women’s health and convenience. This FDA clearance for XACIATO comes barely three years after they licenced the technology.
Moreover, they are appreciative to the FDA for their thorough evaluation and labelling alignment, which provides healthcare practitioners with clear guidance on how to use XACIATO in the most vulnerable patient populations, such as pregnant females with recurrent bacterial vaginosis. They are hopeful that this will be the first of many FDA approvals in their efforts to enhance the lives of women by providing therapeutic alternatives that meet some of the most pressing unmet needs.
David Friend, Daré’s CEO stated that,
Bacterial vaginosis is an excess of bacteria normally prevalent in the vaginal area, rather than a sexually transmitted infection. It disrupts the normal vaginal microbiome’s balance, resulting in not just unpleasant odour and discharge, but also an elevated chance of preterm birth, infertility, and infections in women. In today’s world, around half of all women cured of bacterial vaginosis have a recurrence within a year after treatment.
However, he added that more efficient and helpful treatment alternatives are needed, particularly solutions that enhance clinical outcomes for women who are initially diagnosed with bacterial vaginosis, as well as women who have numerous bouts of bacterial vaginosis each year. Now that they’ve completed this critical demonstration of the drug delivery hydrogel platform technology, they’re looking at how they may apply it to additional unmet requirements in women’s health.
